HPV-16 H-2 Db Restricted E7 Peptide (aa 49-57)-specific CD8+ T Cell Line

Case ID:
C14303
Disclosure Date:
7/27/2016
Description:
UNMET NEED
Human papillomaviruses, particularly HPV-16, are associated with most cervical cancers and their precursors. E7 is an oncogenic HPV protein that is expressed in most HPV-positive cervical carcinomas and plays an important role in the initiation and maintenance of cellular transformation. Accordingly, vaccines targeting the E7 protein appear to be a promising approach to prevent and/or treat HPV-associated cervical malignancies.

FEATURES
Johns Hopkins researchers have generated the HPV-16 E7-specific CD8+ T cell line by vaccinating six week old female C57BL/6 (H-2Db) mice with 107 p.f.u. of Sig/E7/LAMP-1 vaccinia virus through intraperitoneal injection, a vaccine virus that contains and encodes the HPV-E7 protein. The resulted splenocytes were harvested, stimulated with autologous irradiated splenocytes pulsed with HPV-16 E7 peptide (amino acid 49-57), and sorted for E7-specificity and CD8 expression. The resulted E7-specific CD8+ T cell recognizes the HPV-E7 epitope (amino acid 49-57). These T cells can be used to assess HPV-16 E7 processing and presentation by the DCs and to be used to assess the efficacy of adoptive T cell transfer against HPV-E7 expressing tumors in preclinical studies.

STAGE OF DEVELOPMENT
E7 peptide (aa 49-57)-specific CD8+ T cells were characterized by determining the ability of T cells to kill HPV-16 E6 (aa 48-57) peptide-pulsed EL-4 cells and by staining for CD8.

DISEASE INDICATION
Cancer, infectious diseases

ASSOCIATED PUBLICATIONS
?  Gene Ther. 2000 May;7(9):726-33. ?



 
Patent Information:
Inventors:
Category(s):
For Information, Contact:
Christine Joseph
cjoseph6@jhmi.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum